A novel companion diagnostic assay for BRAF V600E/K detection in melanoma: High clinical concordance of patient outcomes for trametinib and debrafenib treatment

被引：0
|
作者：
O'Donnell, L. [1 ]
Sweet, W. [1 ]
Lu, X. [1 ]
Meynier, F. [2 ]
Derome, A. [3 ]
Ganee, L. [3 ]
Poyet-Gelas, F. [3 ]
Martin, A.
Casey, M.
Kertesz, N. [4 ]
机构：
[1] BioMerieux Inc, Clin Affairs, Durham, NC USA
[2] BioMerieux Inc, BioMath, Grenoble, France
[3] BioMerieux Inc, R&D, Grenoble, France
[4] Response Genet Inc, Pharmaceut Liaison, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3720
引用
收藏
页码：S862 / S862
页数：1
相关论文
共 50 条
  • [31] Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
    Wang, Wei
    Smith, Jessica Louise
    Carlino, Matteo Salvatore
    Burmeister, Bryan
    Pinkham, Mark Blayne
    Fogarty, Gerald Blaise
    Christie, David Robert Harry
    Estall, Vanessa
    Shackleton, Mark
    Clements, Arthur
    Wolfe, Rory
    Le Thi Phuong Thao
    Paton, Elizabeth Jane
    Steel, Victoria
    Williams, Narelle Catherine
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2021, 30 : 95 - 99
  • [32] Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
    Gibney, Geoffrey Thomas
    Marynchenko, Maryna
    Galebach, Philip J.
    Ayas, Charles
    Liu, Nathan S.
    Wu, Eric Qiong
    Yim, Yeun Mi
    Abhyankar, Sarang S.
    Reyes, Carolina M.
    Guerin, Annie
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Lung Adenocarcinoma with a Rare BRAF V600E K601_W604del Mutation Responded to Dabrafenib Plus Trametinib Treatment: A Case Report
    Shimizu, J.
    Horio, Y.
    Hida, T.
    Yatabe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1049 - S1049
  • [34] Synthesis and biological evaluation of novel imidazo[2,1-b]oxazole derivatives as V600E BRAF inhibitors for treatment of melanoma
    Abdel-Maksoud, Mohammed
    El-Gamal, Mohammed
    Ammar, Usama
    Ali, Eslam
    Mersal, Karim
    Choi, Hong
    Oh, Chang
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [35] Analytic and Diagnostic Performance of Two Allele-specific PCR Assays for the Clinical Detection of BRAF V600E in Hairy Cell Leukemia
    Brown, N. A.
    Weigelin, H. C.
    Bailey, N. G.
    Laliberte, J.
    Elenitoba-Johnson, K. S.
    Lim, M. S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2012, 14 (06): : 656 - 656
  • [36] Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring
    Pasqualetti, Francesco
    Restante, Giuliana
    Gonnelli, Alessandra
    Rofi, Eleonora
    Molinari, Alessandro
    Crucitta, Stefania
    Paiar, Fabiola
    Ruda, Roberta
    Danesi, Romano
    Soffietti, Riccardo
    Del Re, Marzia
    NEURO-ONCOLOGY, 2019, 21 (12) : 1610 - 1611
  • [37] BRAF(V600E;K601Q) metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy
    Porcelli, Letizia
    Di Fonte, Roberta
    Pierri, Ciro L.
    Fucci, Livia
    Saponaro, Concetta
    Armenio, Andrea
    Serrati, Simona
    Strippoli, Sabino
    Fasano, Rossella
    Volpicella, Mariateresa
    Daprile, Rossana
    Tommasi, Stefania
    Ressa, Cosmo M.
    Guida, Michele
    Azzariti, Amalia
    PHARMACOLOGICAL RESEARCH, 2022, 182
  • [38] Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) with BRAF V600E/K-mutant melanoma in the COMBAT trial
    Robert, Caroline
    Shen, Shensi
    Allard, Delphine
    Fernandez, Ana Arance
    Dutriaux, Caroline
    de Jong, Egbert
    Squires, Matthew
    Grob, Jean-Jacques
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model
    Kawaguchi, Kei
    Igarashi, Kentaro
    Li, Shukuan
    Han, Qinghong
    Tan, Yuying
    Kiyuna, Tasuku
    Miyake, Kentaro
    Murakami, Takashi
    Chmielowski, Bartosz
    Nelson, Scott D.
    Russell, Tara A.
    Dry, Sarah M.
    Li, Yunfeng
    Unno, Michiaki
    Eilber, Fritz C.
    Hoffman, Robert M.
    ONCOTARGET, 2017, 8 (49) : 85516 - 85525
  • [40] Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)
    Puzanov, Igor
    Callahan, Margaret K.
    Linette, Gerald P.
    Patel, Sapna Pradyuman
    Luke, Jason J.
    Sosman, Jeffrey Alan
    Wolchok, Jedd D.
    Hamid, Omid
    Minor, David R.
    Orford, Keith W.
    Hug, Bruce A.
    Ma, Bo
    Matthys, Gemma M.
    Hoos, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345